DE3586536D1 - Monoklonaler antikoerper gegen ein cytotoxin, denselben erzeugendes hybridoma und verfahren fuer die herstellung des gereinigten cytotoxin. - Google Patents

Monoklonaler antikoerper gegen ein cytotoxin, denselben erzeugendes hybridoma und verfahren fuer die herstellung des gereinigten cytotoxin.

Info

Publication number
DE3586536D1
DE3586536D1 DE8585115918T DE3586536T DE3586536D1 DE 3586536 D1 DE3586536 D1 DE 3586536D1 DE 8585115918 T DE8585115918 T DE 8585115918T DE 3586536 T DE3586536 T DE 3586536T DE 3586536 D1 DE3586536 D1 DE 3586536D1
Authority
DE
Germany
Prior art keywords
cytotoxin
production
monoclonal antibody
same
antibody against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585115918T
Other languages
English (en)
Other versions
DE3586536T2 (de
DE122004000005I1 (de
DE3586536T3 (de
Inventor
David Wallach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3586536(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE3586536D1 publication Critical patent/DE3586536D1/de
Publication of DE3586536T2 publication Critical patent/DE3586536T2/de
Publication of DE3586536T3 publication Critical patent/DE3586536T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE3586536T 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin. Expired - Lifetime DE3586536T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL73883A IL73883A (en) 1984-12-20 1984-12-20 Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha

Publications (3)

Publication Number Publication Date
DE3586536D1 true DE3586536D1 (de) 1992-09-24
DE3586536T2 DE3586536T2 (de) 1993-02-18
DE3586536T3 DE3586536T3 (de) 2002-05-08

Family

ID=11055557

Family Applications (5)

Application Number Title Priority Date Filing Date
DE3586536T Expired - Lifetime DE3586536T3 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE19853586536 Pending DE122004000005I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin
DE200412000007 Pending DE122004000007I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE198585115918T Pending DE186833T1 (de) 1984-12-20 1985-12-13 Zytotoxisches protein, verfahren zum isolieren desselben, monoklonaler antikoerper ct-1 und denselben erzeugendes hybridoma.
DE200412000017 Pending DE122004000017I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE19853586536 Pending DE122004000005I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin
DE200412000007 Pending DE122004000007I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE198585115918T Pending DE186833T1 (de) 1984-12-20 1985-12-13 Zytotoxisches protein, verfahren zum isolieren desselben, monoklonaler antikoerper ct-1 und denselben erzeugendes hybridoma.
DE200412000017 Pending DE122004000017I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.

Country Status (9)

Country Link
US (1) US6090923A (de)
EP (1) EP0186833B2 (de)
JP (2) JPS61191620A (de)
AU (1) AU601144B2 (de)
CA (1) CA1337518C (de)
DE (5) DE3586536T3 (de)
IL (1) IL73883A (de)
NL (1) NL300142I2 (de)
ZA (1) ZA859757B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019385A (en) * 1984-11-09 1991-05-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Novel lymphopine LK 2 and pharmaceutic compositions containing same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP3155961B2 (ja) * 1987-12-30 2001-04-16 煕 中島 抗ビリルビンモノクローナル抗体固定担体およびその製造方法
EP0409901A4 (en) * 1988-04-15 1991-10-30 Research Corporation Technologies, Inc Lak cell cytotoxin
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
DE69321909T2 (de) * 1992-08-28 1999-04-01 Bayer Ag Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
US7166423B1 (en) 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
CA2146974C (en) * 1992-10-21 2010-02-02 Andreas Radbruch Direct selection of cells by secretion product
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU228630B1 (en) 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
IL126024A0 (en) * 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
IL178921A0 (en) * 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1450839A4 (de) * 2001-11-06 2009-06-24 Serono Lab Verfahren zur behandlung von auf östrogen ansprechendem brustkrebs
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1733056B1 (de) 2004-03-31 2013-05-22 The General Hospital Corporation Verfahren zur bestimmung des ansprechens eines tumors auf behandlungen mit dem epidermalen wachstumsfaktor-rezeptor als target
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CA2911000A1 (en) 2006-04-05 2007-10-18 Min W. Wan Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
KR101690390B1 (ko) 2007-05-11 2016-12-27 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
EP2225276B1 (de) 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Antikörper gegen tnf-alpha
KR20100120289A (ko) 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
EP2228652A1 (de) 2009-03-11 2010-09-15 Medizinische Universität Wien Verbesserung bei der Tumorbehandlung
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
EP2720721B1 (de) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 als zielmolekül für therapeutische antikörper bei der behandlung von krebs
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014160871A2 (en) 2013-03-27 2014-10-02 The General Hospital Corporation Methods and agents for treating alzheimer's disease
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102617137B1 (ko) 2014-09-15 2023-12-27 칠드런'즈 메디컬 센터 코포레이션 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
JP2023554200A (ja) 2020-12-09 2023-12-26 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4843841B1 (de) * 1969-09-06 1973-12-21
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
CA1208546A (en) * 1981-09-08 1986-07-29 Anthony Cerami Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US5700466A (en) * 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
JPS58138383A (ja) † 1982-02-13 1983-08-17 Nippon Shinyaku Co Ltd 生理活性物質の製法
EP0117705A3 (de) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monocyten und Blastzellen spezifischer monoklonaler Antikörper
JPH0780914B2 (ja) * 1984-04-02 1995-08-30 旭化成工業株式会社 ヒト腫瘍壊死因子に対する抗体
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
DE122009000074I1 (de) * 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.

Also Published As

Publication number Publication date
US6090923A (en) 2000-07-18
DE3586536T2 (de) 1993-02-18
EP0186833B2 (de) 2001-11-28
EP0186833A2 (de) 1986-07-09
NL300142I1 (nl) 2004-04-01
AU5142485A (en) 1986-06-26
IL73883A0 (en) 1985-03-31
DE186833T1 (de) 1986-12-18
EP0186833B1 (de) 1992-08-19
AU601144B2 (en) 1990-09-06
DE122004000017I1 (de) 2005-06-16
JPS61191620A (ja) 1986-08-26
DE122004000005I1 (de) 2006-06-08
ZA859757B (en) 1986-09-24
DE3586536T3 (de) 2002-05-08
CA1337518C (en) 1995-11-07
DE122004000007I1 (de) 2004-07-01
IL73883A (en) 1990-12-23
EP0186833A3 (en) 1987-05-27
JPH0787966A (ja) 1995-04-04
NL300142I2 (nl) 2005-08-01

Similar Documents

Publication Publication Date Title
DE3586536D1 (de) Monoklonaler antikoerper gegen ein cytotoxin, denselben erzeugendes hybridoma und verfahren fuer die herstellung des gereinigten cytotoxin.
DE3689734D1 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
DE3587360D1 (de) Verfahren zur herstellung von chimaerischen monoklonalen antikoerpern.
DE3586822D1 (de) Halbleiteranordnung und verfahren zu deren herstellung.
ATE143376T1 (de) Gegen die beta-kette des leukozyten-adhäsions- rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
DE59105495D1 (de) Thermoplastische Massen für die Herstellung metallischer Formkörper.
NL192157B (nl) Werkwijze voor de vervaardiging van een inductantie-element.
ATE193733T1 (de) Stahl für die herstellung von teilbaren maschinenteilen und maschinenteile, hergestellt aus diesen stahl
DE3581417D1 (de) Lateraler bipolarer transistor und verfahren zu seiner herstellung.
FR2704548B1 (fr) Procédé pour la production de trialcoxysilanes.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
FR2689504B1 (fr) Procédé de production d'hydrocarbures fluorés.
DE69418581T2 (de) Verfahren zur herstellung dünner bleche, geeignet für die anfertigung von dosenteilen
DE3580133D1 (de) N-benzoyl-n'-pyridazinyloxyphenyl harnstoff-verbindungen, diese enthaltende antitumor-zusammensetzungen und verfahren zu deren herstellung.
ES538579A0 (es) Un procedimiento para la produccion de 3,3",4"-tri-o-acilespiramicina i"-.
IT8520246A0 (it) Procedimento stereocontrollato per la produzione di acetossiazetidinone.
DE3574601D1 (de) Antitetanus-antikoerper herstellender human-human-hybridoma und verfahren zu seiner herstellung.
DE69502571T2 (de) Prozess für die Herstellung von fermentierbarem Material
DE3381408D1 (de) Zwischenverbindungen fuer die herstellung von ceftazidin und verfahren zu ihrer herstellung.
DE69332637T2 (de) Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
DE3483098D1 (de) Nagellacke und verfahren zu deren herstellung.
DE69104816D1 (de) Verfahren zur Herstellung von Ammoniak-Synthesegas.
DE3381606D1 (de) Transistor mit heterouebergang und verfahren zu dessen herstellung.
ATA11482A (de) Verfahren zur herstellung von anti-t.lymphozyten -globulin
ITRM940253A0 (it) "procedimento per la produzione di policarbonato".

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
V448 Application of spc

Free format text: PRODUCT NAME: HUMIRA-ADALIMUMAB; REGISTRATION NO/DATE: EU/1/03/256/001 - EU/1/03/256/006; 20030908

Spc suppl protection certif: 12 2004 000 005

Filing date: 20040304

V448 Application of spc

Free format text: PRODUCT NAME: ADALIMUMAB (TRUDEXA); REGISTRATION NO/DATE: EU/1/03/257/001 - EU/1/03/257/006; 20030908

Spc suppl protection certif: 12 2004 000 007

Filing date: 20040324

V448 Application of spc

Free format text: PRODUCT NAME: TRUDEXA-ADALIMUMAB; REGISTRATION NO/DATE: EU/1/03/257/001 - EU/1/03/257/006; 20030901

Spc suppl protection certif: 12 2004 000 017

Filing date: 20040426

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: TRUDEXA-ADALIMUMAB; REGISTRATION NO/DATE: EU/1/03/257/001 - EU/1/03/257/006; 20030901

Spc suppl protection certif: 12 2004 000 017

Filing date: 20040426

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: HUMIRA-ADALIMUMAB; REGISTRATION NO/DATE: EU/1/03/256/001 - EU/1/03/256/006; 20030908

Spc suppl protection certif: 12 2004 000 005

Filing date: 20040304

V457 Spc granted

Free format text: PRODUCT NAME: HUMIRA-ADALIMUMAB; REGISTRATION NO/DATE: EU/1/03/256/001 - EU/1/03/256/006; 20030908

Spc suppl protection certif: 12 2004 000 005

Filing date: 20040304

V472 Withdrawal of application for spc

Free format text: PRODUCT NAME: ADALIMUMAB (TRUDEXA); REGISTRATION NO/DATE: EU/1/03/257/001 - EU/1/03/257/006; 20030908

Spc suppl protection certif: 12 2004 000 007

Filing date: 20040324

V464 Spc expired

Spc suppl protection certif: 12 2004 000 005

Free format text: PRODUCT NAME: HUMIRA-ADALIMUMAB; REGISTRATION NO/DATE: EU/1/03/256/001 - EU/1/03/256/006; 20030908

Filing date: 20040304